Products of conception genetic testing analyzes placental or fetal tissue from a miscarriage to determine whether a chromosome abnormality may explain the loss. The most commonly used modern method is chromosomal microarray, often a single-nucleotide polymorphism array that can detect extra or missing chromosomes, many segmental deletions and duplications, triploidy, and maternal cell contamination. A result can identify a sporadic aneuploidy, show a chromosomally typical result, reveal an unbalanced rearrangement that prompts parental testing, or fail because the submitted material did not contain enough pregnancy tissue. POC testing cannot prove that a chromosome finding was the only cause of miscarriage, and a normal result does not identify all nonchromosomal causes. Its usefulness depends heavily on specimen collection: maternal decidua can be mistaken for chorionic villi and produce a misleading 46,XX result. Testing may provide an explanation and guide recurrent-pregnancy-loss evaluation, but it is not mandatory after every miscarriage. The decision should reflect the number and timing of losses, tissue availability, cost, emotional goals, and how the result would change future care.
- POC testing examines tissue from the pregnancy, not the parents’ blood.
- SNP-based chromosomal microarray is often preferred because it does not require living cells and can assess maternal contamination.
- An abnormal result often reflects a sporadic chromosome error, especially after an early miscarriage.
- A 46,XX or “normal female” result may be maternal tissue unless contamination testing confirms fetal origin.
- A normal or euploid result does not exclude single-gene, placental, uterine, endocrine, immune, or unexplained causes.
- Certain unbalanced results should lead to parental karyotyping and genetic counseling.
Table of Contents
- What POC genetic testing can find
- Who may consider testing
- Collecting and preparing the specimen
- Microarray, karyotype, and other methods
- How to read POC results
- How results shape future evaluation
- Limitations, emotional impact, and next steps
What POC genetic testing can find
Chromosome abnormalities are common in early pregnancy loss. Many arise from random errors during egg or sperm formation or during the first cell divisions after fertilization. The likelihood of aneuploid conception rises with maternal age because chromosome-separation errors become more frequent in oocytes, although miscarriage can occur at any age.
POC testing can identify whole-chromosome aneuploidy, such as trisomy 16, trisomy 22, trisomy 21, monosomy X, or combinations involving several chromosomes. It can also detect triploidy, in which the pregnancy has three complete chromosome sets, if the chosen method is capable of recognizing ploidy. Tetraploidy and some mosaic results may be detected depending on platform and specimen quality.
A chromosomal microarray can find segmental gains and losses that are smaller than a whole chromosome. These may represent a de novo copy-number variant or the unbalanced product of a parental translocation or inversion. The pattern of duplicated and deleted segments can suggest a structural rearrangement even though the array cannot directly show a balanced chromosome architecture.
Some laboratories classify copy-number changes as pathogenic, likely pathogenic, uncertain, likely benign, or benign. A variant of uncertain significance does not establish the cause of miscarriage. Its relevance depends on the region, size, gene content, inheritance, and whether similar changes are known in viable individuals.
SNP-based arrays provide additional information. They can detect long regions of homozygosity, help identify triploidy and uniparental patterns, and compare the tissue genotype with maternal blood to detect maternal cell contamination. Some can indicate androgenetic or biparental origin in suspected molar pregnancy, but specialized pathology and molecular testing may still be required.
A chromosome abnormality found in POC can offer a plausible explanation, but causation should be expressed carefully. Some aneuploidies are strongly incompatible with normal development and are highly likely to explain the loss. Other findings can be viable with variable outcomes, so the clinical context and pathology matter.
A euploid result means the assay found the expected chromosome dosage. It does not prove that the embryo or fetus was genetically normal. Single-gene variants, epigenetic disorders, low-level mosaicism, and changes below the platform’s resolution can remain undetected. Non-genetic causes also remain possible.
Who may consider testing
POC testing may be discussed after a first miscarriage, but professional practices and insurance coverage vary. Some patients want an explanation immediately; others prefer not to test because a single early loss is common and the result may not change management. Neither choice is inherently better.
The test becomes particularly useful in recurrent pregnancy loss, often defined as two or more pregnancy losses in current guidelines. The 2026 ASRM committee opinion recommends chromosome analysis of miscarriage tissue, when feasible, as a first step in evaluating a couple with recurrent loss and supports array-based technology because of its technical advantages over traditional cytogenetics. ESHRE’s updated guideline also supports genetic analysis of pregnancy tissue for explanatory purposes under appropriate counseling, while emphasizing method and contamination safeguards.
Testing can help distinguish a likely sporadic aneuploid loss from a chromosomally typical loss. This distinction may guide the order and urgency of additional investigations, but it should not be used to deny a full evaluation when clinical history warrants one. An aneuploid result does not make uterine, endocrine, or antiphospholipid factors impossible.
Testing may also be useful after a second-trimester loss, fetal anomaly, stillbirth, or suspected molar pregnancy. The appropriate assay and accompanying pathology differ from routine early miscarriage. In later losses, clinicians may request chromosomal microarray, karyotype, targeted testing, infection studies, autopsy, or placental pathology based on the presentation.
A known parental balanced translocation or inversion is another indication. If a pregnancy is lost, POC testing can determine whether the conceptus had an unbalanced chromosome complement. The test design should be coordinated with a cytogenetics laboratory because a dosage-only array cannot distinguish a normal result from inheritance of the same balanced parental rearrangement.
Tissue availability influences the decision. Genetic testing is easiest when the loss is managed surgically or when passed tissue can be collected promptly and correctly. With expectant or medication management, patients should receive clear instructions and a collection container if testing is desired. Sending every blood clot without identifying villi increases failure and contamination.
Cost, turnaround, and emotional goals matter. Some people seek closure; others worry that uncertain results will increase distress. Pretest counseling should explain all possible result categories—including no result—so testing is chosen for realistic reasons.
Collecting and preparing the specimen
Specimen quality is the foundation of a reliable POC result. Products of conception may include chorionic villi, gestational sac, fetal tissue, umbilical cord, and placental tissue. Maternal decidua and blood are often mixed with them. The laboratory needs tissue that truly belongs to the pregnancy.
Chorionic villi are branching placental structures that may appear delicate or frond-like. In a clinical setting, trained staff or pathology personnel can separate villi from maternal decidua under magnification. Visual identification is imperfect, especially in very early losses or fragmented specimens, so molecular maternal-contamination testing remains valuable.
For surgical management, the clinician should follow the laboratory’s collection protocol and avoid placing all tissue in formalin if molecular testing is planned. Formalin can damage DNA, although some laboratories validate testing on fixed tissue. Fresh tissue is typically placed in sterile transport medium or another specified container—not saline, water, or alcohol unless instructed.
For tissue passed at home, the clinic or laboratory should provide written instructions. The specimen may need refrigeration and prompt delivery. Freezing, room-temperature storage, or transport requirements vary. Patients should not be expected to dissect tissue themselves without support, and they should be warned that the visible material may be emotionally difficult to handle.
A maternal blood or buccal sample is often requested with the POC. SNP comparison can confirm whether the tested DNA is fetal/placental, maternal, or mixed. This is especially important for a 46,XX-equivalent result because maternal cells also carry two X chromosomes. Without contamination studies, a report of “normal female” may falsely appear reassuring.
Pathology examination and genetic testing answer different questions. Pathology can confirm chorionic villi, evaluate molar changes, and identify inflammation or placental abnormalities. Genetics evaluates chromosomes or DNA. Coordinating both prevents the entire specimen from being consumed by one service and preserves material for the other.
Chain of custody, labeling, and pregnancy identification matter when more than one specimen is involved. The requisition should include gestational age, management method, ultrasound findings, fetal sex if known, parental rearrangements, and whether twins or a vanishing twin were present. This context helps the laboratory interpret mosaic and mixed results.
Microarray, karyotype, and other methods
SNP chromosomal microarray is widely favored for POC because it analyzes DNA directly and usually does not require cell culture. It can detect aneuploidies, many deletions and duplications, triploidy, regions of homozygosity, and maternal contamination when a maternal comparator is available. Success rates are generally higher than culture-based karyotyping in degraded tissue.
Array comparative genomic hybridization also detects gains and losses but may not detect triploidy because all chromosomes are increased proportionally. It cannot identify copy-neutral regions of homozygosity. The report or test menu should specify whether the platform is SNP-based or array-CGH.
Conventional karyotyping grows cells and examines chromosomes under a microscope. It can reveal balanced and unbalanced translocations, inversions, polyploidy, and large abnormalities. Its disadvantages are culture failure, slower turnaround, lower resolution, and preferential growth of maternal cells. A 46,XX result from culture is particularly vulnerable to maternal overgrowth.
QF-PCR or FISH can rapidly test selected chromosomes and may detect common aneuploidies or triploidy. They are targeted and can miss abnormalities outside the probe or marker set. Some laboratories combine rapid testing with microarray to improve speed and scope.
Next-generation sequencing–based copy-number testing can assess all chromosomes using low-pass sequencing. It may have high success in poor-quality tissue, but capabilities for triploidy, maternal contamination, mosaicism, and balanced rearrangements differ by assay.
Exome or genome sequencing is not routine POC testing after an uncomplicated early miscarriage. It may be considered in research or selected recurrent, structurally abnormal, or consanguineous cases after chromosome testing is normal. Interpretation is challenging because a pathogenic variant found in fetal tissue is not necessarily the cause of death, and parental samples are often needed.
No single method detects everything. A balanced parental translocation can produce a euploid array result if the conceptus inherited the balanced form. Low-level mosaicism can be missed. Tetraploidy may be invisible to some arrays. The ordering clinician should match the technology to the clinical question rather than accepting a generic “POC panel.”
How to read POC results
An aneuploid result names an extra or missing chromosome. A single trisomy in an early miscarriage is usually sporadic. The recurrence chance is influenced mainly by maternal age and pregnancy history rather than by the fact that the same exact trisomy occurred once. Exceptions include patterns suggesting a parental structural rearrangement.
A result with both a deletion and duplication on different chromosomes may indicate an unbalanced translocation. For example, loss from the end of one chromosome plus gain from another can reflect a balanced translocation in a parent. Parental karyotypes are then important because future recurrence risk and reproductive options differ from those after a random trisomy.
Triploidy can arise from an extra paternal or maternal chromosome set. Pathology, ultrasound, and molecular markers may help distinguish mechanisms, especially when a partial molar pregnancy is suspected. Follow-up of human chorionic gonadotropin and future-pregnancy counseling may differ for molar disease.
A euploid male result is strong evidence that pregnancy tissue was tested because maternal tissue would not contain a Y chromosome, although contamination or sample mix-up can still complicate rare cases. A euploid female result requires evidence that the sample was not maternal. Reports may state that maternal cell contamination was excluded, detected, or could not be assessed.
A maternal cell contamination result means the DNA came partly or entirely from the patient rather than the pregnancy. A pure maternal result is not informative about the miscarriage chromosomes. The laboratory may attempt testing another tissue block or villous sample if available.
A mosaic result indicates more than one cell population. It may reflect true embryonic or placental mosaicism, maternal mixture, culture artifact, or technical noise. The platform’s detection threshold and the tissue tested matter. A reported percentage is an estimate for that specimen, not a map of the entire pregnancy.
A variant of uncertain significance is a copy-number change whose health effect is unclear. Parental testing may show that it was inherited from a healthy parent, which can reduce concern but does not automatically make it benign. It should not be labeled the cause of miscarriage without supporting evidence.
A no result may be caused by insufficient tissue, degraded DNA, contamination, failure of culture, or a sample that contained only blood clot and decidua. Failure does not imply a normal or abnormal pregnancy. The clinic should determine whether retained tissue can be retested with another method.
How results shape future evaluation
A clearly sporadic aneuploid result can provide an explanation and may reduce suspicion that the loss resulted from something the patient did. It can also prevent unnecessary treatment. However, it should not be used to dismiss recurrent-loss evaluation when the patient meets criteria or has other clinical indications.
A euploid loss can increase attention to non-aneuploid causes: uterine anatomy, antiphospholipid syndrome, thyroid disease, diabetes when indicated, parental chromosome rearrangements, and selected other factors. Many euploid losses remain unexplained even after evaluation. The result should guide priorities rather than promise that another cause will be found.
An unbalanced structural result should prompt parental karyotype testing. If one partner carries a balanced rearrangement, counseling can cover natural conception with prenatal diagnosis, IVF with PGT-SR, donor gametes, adoption, and the possibility of live birth without intervention. Management is individualized; a carrier result does not automatically require IVF.
Repeated POC results can reveal patterns. Different sporadic trisomies across losses often point to age-related aneuploidy rather than a single inherited rearrangement. Repeatedly euploid losses may strengthen the rationale for a comprehensive recurrent-loss evaluation. Recurrent similar segmental imbalances increase concern for a parental structural change.
A POC result cannot predict ovarian reserve or guarantee the chromosome status of the next pregnancy. It describes one conception. PGT-A may reduce transfer of aneuploid embryos in IVF, but evidence for improving cumulative live birth in recurrent loss is context-dependent and should not be presented as a direct treatment for every abnormal POC result.
Results may influence whether early diagnostic testing is desired in a future pregnancy. A familial rearrangement can be tested by CVS or amniocentesis. After a sporadic aneuploid loss, patients may choose routine screening, cell-free DNA, or diagnostic testing according to age and preferences.
Limitations, emotional impact, and next steps
POC genetic testing can explain a chromosome mechanism but cannot answer why the error occurred in a personal or moral sense. Most sporadic aneuploidies are random biological events and are not caused by exercise, sex, ordinary work, stress, or a minor action during pregnancy.
The test may not identify the cause. A normal result leaves many possibilities, and an uncertain result can create new questions. Even an abnormal result may not fully explain later losses. Counseling should avoid treating one laboratory finding as a complete theory of the patient’s reproductive history.
Specimen errors are a major limitation. Maternal contamination, wrong tissue, sample mix-up, formalin damage, and delayed transport can produce false reassurance or no result. Confirming villi and using a maternal comparator substantially improve reliability.
Insurance coverage and access differ. Patients should ask about laboratory fees, maternal contamination testing, pathology charges, and whether parental follow-up is included. They should also ask how long tissue is retained in case additional testing becomes necessary.
The emotional response varies. An aneuploid result can bring relief, grief, guilt, or fear about age and future pregnancies. A euploid result can intensify the search for an explanation. A no-result can feel like a second loss of information. Results should be delivered with acknowledgment of the miscarriage, not as an impersonal laboratory update.
After testing, the clinician should document the exact method and full report, not just “normal” or “abnormal.” That record can prevent duplicate testing and guide future genetics consultation. If recurrent loss criteria are met, POC testing should be integrated with—not substituted for—a structured evaluation.
The best POC test is one ordered with a plan for every possible outcome. Before collection, patients should know what the assay can detect, how fetal tissue will be verified, and what abnormal, euploid, uncertain, contaminated, or failed results would change. That preparation makes the information more medically useful and less likely to be misinterpreted.
Special situations can change how a POC result should be interpreted
A result may need extra context when the pregnancy involved twins, a vanishing twin, an embryo created with donor gametes, or a prior transplant. In a multifetal pregnancy, the submitted tissue may represent one conceptus, mixed tissue from more than one conceptus, or tissue whose origin cannot be determined confidently. The laboratory should be told about these circumstances before testing so it can select the most appropriate method and explain any limitations in the report.
Keep the complete laboratory report, not only the one-line result. Future clinicians may need the chromosome notation, platform, quality metrics, maternal-cell-contamination findings, and the laboratory’s interpretation to decide whether parental testing or a different reproductive plan is appropriate. Families should also ask how remaining tissue and extracted DNA will be stored or discarded. Retaining a specimen or DNA aliquot, when available and permitted, can be useful if new information later changes the interpretation or if confirmatory testing becomes necessary.
References
- Recurrent Pregnancy Loss: A Committee Opinion (2026), ASRM practice guideline.
- ESHRE Guideline: Recurrent Pregnancy Loss (2023), clinical guideline.
- Evaluation of Recurrent Pregnancy Loss (2024), clinical review.
- Role of Genetic Analysis of Products of Conception and Preimplantation Genetic Testing in Recurrent Pregnancy Loss (2024), clinical review.
- Application of Chromosomal Microarray Analysis in Genetic Reasons of Miscarriage (2024), cohort study.
- Chromosomal Microarray, Autopsy, Products of Conception, or Stillbirth (2025), laboratory guidance.
Disclaimer
This article is for general education and does not replace care from an obstetrician, reproductive endocrinologist, pathologist, or genetic counselor. Testing methods, specimen requirements, reporting, and insurance coverage vary by laboratory and location. Miscarriage symptoms can require urgent medical assessment regardless of whether tissue testing is planned.
